EW Stock Analysis — Edwards Lifesciences
Sector: Healthcare
AI Verdict
Edwards Lifesciences trades at 30.5x next year's earnings with 60.5% growth expected, so you’re paying up but not overpaying if their clinical moat holds—this is cheap for the growth on offer if their innovation pipeline delivers.
Competitive Moat
Edwards Lifesciences dominates the transcatheter heart valve market with proprietary valve technologies and long-term clinical data that create high switching costs for hospitals and surgeons. Their deep relationships with cardiac centers and ongoing innovation pipeline reinforce their defensibility against generic and new entrants.
Summary
A 60.5% jump in expected earnings is resetting the valuation narrative for this medtech giant.
Where It Stands
Up 19.44% in the past year with an RSI of 68.8 (elevated), EW trades at 30.5x forward earnings versus the 22x sector median, so the market is pricing in rapid growth.
Key Metrics
- RSI: 68.8 — Near Overbought
- Trailing P/E: 49.0x
- Forward P/E: 30.5x
- PEG Ratio: 0.80
- Earnings Growth: +0.6%
- Revenue Growth: +0.1%
- Market Cap: $53.0B
- 1-Year Return: 19.44%
- 52-Week High: $92.88
- 52-Week Low: $72.30
Analyst Consensus
31 Buy · 11 Hold · 0 Sell (42 analysts)
Bull Case
You’re paying 30.5x next year’s earnings for a business expected to grow EPS by 60.5%, which is cheap for the growth if their valve franchise keeps its clinical edge.
Bear Case
With an RSI of 68.8 and a trailing P/E of 49.0x, any disappointment could trigger a sharp pullback as the stock is priced well above the sector’s 22x average.
Catalyst to Watch
Watch for upcoming clinical trial readouts or FDA approvals—positive results could justify the premium, while setbacks may pressure the multiple.